WHO ICTRP trial
[M16-191] Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus…
JPRN-jRCT2041210045 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2041210045 |
|---|---|
| Public title | [M16-191] Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus Ruxolitinib |
| Scientific title | [M16-191] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1) |
| Primary sponsor | Okubo Sumiko |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Australia;Japan;Austria;Japan;Belgium;Japan;Canada;Japan;France;Japan;Germany;Japan;Israel;Japan;Italy;Japan;Netherlands;Japan;Russia;Japan;Korea;Japan;Spain;Japan;Sweden;Japan;Taiwan;Japan;United… |
| Conditions | Myelofibrosis |
| Interventions | Experimental: Arm A: Navitoclax + Ruxolitinib - Participants will receive Navitoclax in combination with Ruxolitinib Active Comparator: Placebo for Navitoclax + Ruxolitinib - Participants will receive placebo for Navitoclax and Ruxolitinib |
| Registration date | Jul 30, 2021 |
| Target size | 23 |
| Secondary IDs | NCT04472598 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: